{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:39:15Z","timestamp":1792654755232,"version":"4.5.0"},"reference-count":54,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Misuse"],"DOI":"10.1080\/10826084.2026.2748450","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:58:33Z","timestamp":1792652313000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A Target Product Profile Framework to Guide Patient-Centered Development, Regulatory Approval, and Market Access of Digital Therapeutics for Substance Use Disorders"],"prefix":"10.1080","author":[{"given":"Leonardo M.","family":"Angelone","sequence":"first","affiliation":[{"name":"Office of Translational Initiatives and Program Innovations, National Institute on Drug Abuse (NIDA), National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Office of Translational Initiatives and Program Innovations, National Institute on Drug Abuse (NIDA), National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Koustova","sequence":"additional","affiliation":[{"name":"Office of Translational Initiatives and Program Innovations, National Institute on Drug Abuse (NIDA), National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_3_1","unstructured":"Biomedical Advanced Research and Development Authority. (n.d.). Target product profiles. U.S. Department of Health and Human Services. https:\/\/medicalcountermeasures.gov\/barda\/tpp"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2196\/44764"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2017.02.011"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2025.00240"},{"key":"e_1_3_3_7_1","unstructured":"Centers for Disease Control and Prevention. (2025). National Center for Health Statistics mortality data on CDC WONDER current final multiple cause of death data. https:\/\/wonder.cdc.gov\/mcd.html"},{"key":"e_1_3_3_8_1","unstructured":"Centers for Medicare & Medicaid Services. (2024\/2025). Medicare and Medicaid programs; CY 2025 payment policies under the physician fee schedule and other changes. Federal Register 89 FR (Dec. 9 2024). https:\/\/www.federalregister.gov\/documents\/2024\/12\/09\/2024-25382\/"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-026-02343-9"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.22.289521"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2019.27.1.6"},{"key":"e_1_3_3_12_1","unstructured":"Code of Federal Regulations Title 21 \u00a7 814.20(b)(3)(i). (2026). https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-814\/subpart-B\/section-814.20"},{"key":"e_1_3_3_13_1","unstructured":"Code of Federal Regulations Title 21 \u00a7 882.5801. (2022). Computerized behavioral therapy device for psychiatric disorders. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H\/part-882\/subpart-F\/section-882.5801"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-021-00517-1"},{"key":"e_1_3_3_15_1","unstructured":"Digital Medicine Society. (n.d.). Target patient value profile (TPVP) template for digital health technologies (DHTs). https:\/\/dimesociety.org\/resources\/target-patient-value-profile-tpvp-template-for-digital-health-technologies-dhts\/"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44184-025-00174-2"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05476-1"},{"key":"e_1_3_3_18_1","unstructured":"Institute for Clinical and Economic Review. (2020). Digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder: Effectiveness and value. https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_Digital_Therapeutics_for_OUD_Evidence_Report.pdf"},{"key":"e_1_3_3_19_1","unstructured":"International Medical Device Regulators Forum. (2013). Software as a medical device (SaMD): Key definitions. https:\/\/www.imdrf.org\/sites\/default\/files\/docs\/imdrf\/final\/technical\/imdrf-tech-131209-samd-key-definitions-140901.pdf"},{"key":"e_1_3_3_20_1","unstructured":"International Organization for Standardization. (2023). ISO\/TR 11147:2023 Health informatics - Personalized digital health - Digital therapeutics health software systems. https:\/\/www.iso.org\/obp\/ui\/"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.11.1318"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.2196\/33073"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2196\/49208"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-02264-z"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.03.007"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.823977"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/frhs.2025.1537016"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-02873-1"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coisb.2020.07.004"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0111-3"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.2196\/59088"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104573"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.20.0123"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-00370-8"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10536"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-026-02502-y"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025374"},{"key":"e_1_3_3_39_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2025). Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health (HHS Publication No. PEP25-07-007 NSDUH Series H-60). https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh-national-surveydrug-use-and-health\/national-releases"},{"key":"e_1_3_3_40_1","unstructured":"Tai J. Goh E. Wenzlau M. Avancha S. & Schulman K. (2023). Pear Therapeutics\u2019 failure: Paying the trailblazer tax (Stanford Graduate School of Business\/HMPI Case SM-369). https:\/\/hmpi.org\/wp-content\/uploads\/2023\/12\/SM369-Pear-Therapeutics-10-18-23FINAL.pdf"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.21037\/mhealth-25-24"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.264"},{"key":"e_1_3_3_43_1","unstructured":"U.S. Food and Drug Administration. (2007). Draft guidance for industry and review staff on target product profile - A strategic development process tool. https:\/\/www.federalregister.gov\/documents\/2007\/03\/30\/E7-5949\/draft-guidance-for-industry-and-review-staff-on-target-product-profile-a-strategic-development"},{"key":"e_1_3_3_44_1","unstructured":"U.S. Food and Drug Administration. (2017). Device classification under Section 513(f)(2) (De Novo): Pear Therapeutics Inc. reSET. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN160018"},{"key":"e_1_3_3_45_1","unstructured":"U.S. Food and Drug Administration. (2018). 510(k) premarket notification database: Pear Therapeutics Inc. reSET-O. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K173681"},{"key":"e_1_3_3_46_1","unstructured":"U.S. Food and Drug Administration. (2023). Content of premarket submissions for device software functions. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/content-premarket-submissions-device-software-functions"},{"key":"e_1_3_3_47_1","unstructured":"U.S. Food and Drug Administration. (2024). Clinical considerations for studies of devices intended to treat opioid use disorder. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-considerations-studies-devices-intended-treat-opioid-use-disorder"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1966187"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-02298-7"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00777-z"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.948161"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15685"},{"key":"e_1_3_3_53_1","unstructured":"World Health Organization. (2020). Target product profiles for COVID-19 diagnostics. https:\/\/www.who.int\/publications\/m\/item\/target-product-profiles-for-covid-19-diagnostics"},{"key":"e_1_3_3_54_1","unstructured":"World Health Organization. (2024). Target product profile database. https:\/\/www.who.int\/tools\/target-product-profile-database"},{"key":"e_1_3_3_55_1","unstructured":"World Health Organization. (n.d.). WHO target product profiles. https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/analyses-and-syntheses\/target-product-profile\/who-target-product-profiles"}],"container-title":["Substance Use &amp; Misuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10826084.2026.2748450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10826084.2026.2748450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10826084.2026.2748450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:58:35Z","timestamp":1792652315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10826084.2026.2748450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":54,"alternative-id":["10.1080\/10826084.2026.2748450"],"URL":"https:\/\/doi.org\/10.1080\/10826084.2026.2748450","relation":{},"ISSN":["1082-6084","1532-2491"],"issn-type":[{"value":"1082-6084","type":"print"},{"value":"1532-2491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}